Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OGEN | US
0.01
1.75%
Healthcare
Biotechnology
30/06/2024
08/06/2026
0.60
0.61
0.61
0.58
Oragenics Inc. a development-stage company engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1 an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04 a weight loss candidate; and SMaRT Replacement Therapy a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen Inc. Oragenics Inc. was incorporated in 1996 and is headquartered in Tampa Florida.
View LessLow Market Beta (-0.4 to 0.8)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
21.4%1 month
42.1%3 months
75.0%6 months
81.4%-
-
7.57
-
-
0.21
105.83
-
-19.64M
6.37M
6.37M
-
-263.29K
-
-91.30
-454.72
0.25
1.45
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.07
Range1M
0.10
Range3M
0.61
Rel. volume
0.42
Price X volume
14.94K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| XORTX Therapeutics Inc. Common Stock | XRTX | Biotechnology | 2.18 | 6.56M | -1.36% | n/a | 3.09% |
| Aptorum Group Limited | APM | Biotechnology | 1.17 | 6.40M | 15.84% | n/a | 13.53% |
| Common Stock | ADXN | Biotechnology | 5.86 | 6.26M | 0.00% | n/a | 0.25% |
| Galera Therapeutics Inc | GRTX | Biotechnology | 0.0976 | 5.41M | 2.74% | n/a | -0.87% |
| China SXT Pharmaceuticals Inc | SXTC | Drug Manufacturers-Specialty & Generic | 1.55 | 5.39M | 7.64% | n/a | 19.00% |
| Alzamend Neuro Inc. Common Stock | ALZN | Biotechnology | 1.16 | 5.19M | 4.50% | n/a | 0.00% |
| Pulmatrix Inc | PULM | Biotechnology | 1.42 | 5.19M | 6.77% | n/a | 0.18% |
| Biofrontera Inc. Common Stock | BFRI | Drug Manufacturers-Specialty & Generic | 0.93 | 5.16M | -0.53% | n/a | 13.20% |
| Cadrenal Therapeutics Inc. Common Stock | CVKD | Biotechnology | 4.21 | 4.98M | -5.18% | n/a | 0.22% |
| Xenetic Biosciences Inc | XBIO | Biotechnology | 3.09 | 4.77M | 0.00% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.49 | 3.81M | 12.88% | n/a | 17.32% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0058 | 534.84K | n/a | -37.05% | |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4181 | 230.37K | 7.87% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.21 | 0.53 | Cheaper |
| Ent. to Revenue | 105.83 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 7.57 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 75.04 | 72.80 | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 6.37M | 3.66B | Emerging |